drugset / Trial / NCT02494258
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
NaSingle-groupOpen-labelTreatment
Summary
Rollover study supporting hematological disorder indications from Celgene sponsored CC-486 (oral azacitidine) protocols eligible for participation in the study.
Timeline
- Start
- 2015-10-22
- Primary completion
- 2025-04-14
- Completion
- 2025-04-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CC-486 | Unknown | — | Oral |